Germantown biotech firm
Neuraly is a step closer to achieving a potential breakthrough treatment for Parkinson's disease. The first patient has just been dosed in the Phase 2 clinical trial of their NLY01 product, a glucagon-like peptide 1 receptor (GLP-1R) agonist.
Testing so far has shown that NLY01 was effective in preventing neuronal cell death, as well as preventing the decline of motor skills frequently found in Parkinson's patients. Neuraly is located on Goldenrod Lane, in the Germantown Innovation Center.
No comments:
Post a Comment